Roy van der Meel is Assistant Professor of Precision Medicine at the TU/e's Biomedical Engineering department. His research is focused on developing RNA-based nanotherapeutics to regulate the immune response in a highly precise manner.
Roy van der Meel studied Biomedical Sciences and Drug Innovation at Utrecht University in The Netherlands where he obtained his M.Sc. degree in 2009. He then conducted his Ph.D. research at the Utrecht University Pharmaceutics Department under supervision of Wim Hennink, Gert Storm, Robbert Jan Kok and Raymond Schiffelers. Roy's research focused on developing nanomedicines to inhibit tumor growth and angiogenesis and he obtained his Ph.D. degree in 2013. After obtaining Marie Skłodowska-Curie Action funding from the European Commission and a Veni grant from the Netherlands Organization for Scientific Research, Roy conducted postdoctoral research in the labs of Raymond Schiffelers (University Medical Center Utrecht) and Pieter Cullis (University of British Columbia, Vancouver, BC, Canada). In 2019, Roy was appointed Assistant Professor of Precision Medicine at the TU/e's Biomedical Engineering department.
Lipid nanoparticles to silence androgen receptor variants for prostate cancer therapyJournal of Controlled Release (2022)
Modular Lipid Nanoparticle Platform Technology for siRNA and Lipophilic Prodrug DeliverySmall (2021)
What does the success of mRNA vaccines tell us about the future of biological therapeutics?Cell Systems (2021)
Nanoengineering Apolipoprotein A1-Based ImmunotherapeuticsAdvanced Therapeutics (2021)
Author CorrectionNature Nanotechnology (2021)
Current Educational Activities
- Retained consultancy, Carnot Pharma, LLC d/b/a RAVentures